Alexion to Acquire Achillion
Dateline City: BOSTON & BLUE BELL, Pa. - Adds clinical-stage portfolio of oral small molecule Factor D inhibitors to Alexion’s pipeline - - Provides opportunity to enhance treatment for PNH...
View ArticleAlexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical...
Dateline City: BOSTON - At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - BOSTON--(BUSINESS WIRE)--Alexion...
View ArticleAlexion Reports Third Quarter 2019 Results
Dateline City: BOSTON 3Q19 total revenues of $1,263.1 million, a 23 percent increase over 3Q18 and a 23 percent volume increase 3Q19 GAAP diluted EPS of $2.08; non-GAAP diluted EPS of $2.79 Received 2...
View ArticleAlexion Announces Data Presentations at 61st American Society of Hematology...
Dateline City: BOSTON - Accepted abstracts include presentations of ULTOMIRIS® (ravulizumab-cwvz) Phase 3 PNH data through 52 weeks - - ULTOMIRIS is the first and only long-acting C5 complement...
View ArticleClik here to view.
Alexion to Present at the 2019 Stifel Healthcare Conference
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday,...
View ArticleSOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of...
Dateline City: BOSTON - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Japan - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were...
View ArticleClik here to view.
Alexion to Present at the 2019 Evercore ISI HealthCONx
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December...
View ArticleAlexion Issues Statement on Path to Value Creation
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team: "The Board and...
View ArticleAlexion Exercises Option for Two Additional GalXC™ RNAi Programs for...
Dateline City: BOSTON & LEXINGTON, Mass. – Option Exercise Triggers $20 Million Payment to Dicerna – BOSTON & LEXINGTON, Mass.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and...
View ArticleClik here to view.
Alexion to Present at the 38th Annual J.P Morgan Healthcare Conference
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 38th Annual J.P Morgan Healthcare Conference in San Francisco,...
View ArticleAlexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS®...
Dateline City: BOSTON - 50-week global study to enroll ~350 patients across broad ALS population - BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the planned...
View ArticleAlexion to Report Fourth Quarter and Full Year 2019 Results on Thursday,...
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year...
View ArticleUPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference...
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on...
View ArticleAlexion Completes Acquisition of Achillion
Dateline City: BOSTON – Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases –...
View ArticleAlexion Reports Fourth Quarter and Full Year 2019 Results
Dateline City: BOSTON 4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18 4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71 Received Japanese approval for SOLIRIS®...
View Article
